Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 6/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20150349 | 0.95 | CYP11B1 (0.35) | PTGER4CYP11B1CYP11B2TNKS2FLT3 | |
| SCHEMBL20156264 | 0.92 | PTGER4 (0.37) | PTGER4CYP11B1CYP11B2PDE10ATNKS2 | |
| SCHEMBL20114687 | 0.90 | PTGER4 (0.35) | PTGER4CYP11B1CYP11B2PDE10AMEN1 | |
| SCHEMBL20114553 | 0.90 | PTGER4 (0.36) | PTGER4PDE10AMEN1KMT2AATM | |
| SCHEMBL20150371 | 0.90 | PTGER4 (0.38) | PTGER4CYP11B1CYP11B2PDE10AMEN1 | |
| SCHEMBL19943114 | 0.89 | PTGER4 (0.36) | PTGER4PDE10AMEN1KMT2AATM | |
| SCHEMBL20114689 | 0.89 | PTGER4 (0.36) | PTGER4PDE10AMEN1KMT2AATM | |
| SCHEMBL20114643 | 0.89 | PTGER4 (0.39) | PTGER4PDE10AMEN1KMT2AATM | |
| SCHEMBL21109692 | 0.88 | CYP1A2 (0.33) | PTGER4 | |
| SCHEMBL20114652 | 0.88 | PTGER4 (0.36) | PTGER4CYP11B1CYP11B2PDE10AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10421746-B2 | Organic molecules, especially for use in organic optoelectronic devices | CYNORA GMBH (DE) | 2019-09-24 | — | — | US | disclosed |
| US-20180134686-A1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2018-05-17 | — | — | US | disclosed |
| US-20180134686-A1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | CYNORA GMBH (DE) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134686-A1 | ORGANIC MOLECULES, ESPECIALLY FOR USE IN ORGANIC OPTOELECTRONIC DEVICES | OR10J3, EPCAM, F12 | PTGER4 1809/4885CYP11B1 1765/4885CYP11B2 1259/4885 |
| US-10421746-B2 | Organic molecules, especially for use in organic optoelectronic devices | OR10J3, EPCAM, F12 | PTGER4 1809/4885CYP11B1 1765/4885CYP11B2 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.